View Older Stories View More Recent Stories

Sep 3, 2019 08:01AM Ardelyx (ARDX) announces AMPLIFY study met primary endpoint and all key secondary endpoints
Sep 3, 2019 08:00AM Ardelyx Announces Positive Results from the Pivotal Phase 3 AMPLIFY Study Evaluating Tenapanor in Dialysis Patients Who Have Uncontrolled Hyperphosphatemia Despite Phosphate Binder Treatment
Sep 2, 2019 04:00PM Ardelyx to Host Conference Call on September 3 to Review Results from the Pivotal Phase 3 AMPLIFY Study
Aug 9, 2019 08:00AM Ardelyx Reports Second Quarter 2019 Financial Results and Recent Business Highlights
May 30, 2019 09:00AM Ardelyx to Present at the Jefferies 2019 Global Healthcare Conference
May 7, 2019 04:02PM Ardelyx Reports First Quarter 2019 Financial Results and Recent Business Highlights
Mar 14, 2019 05:08PM Ardelyx (ARDX) Announces Geoffrey A. Block M.D. to Board
Mar 14, 2019 05:00PM Ardelyx Appoints Renowned Nephrologist, Geoffrey A. Block, M.D., to Its Board of Directors
Mar 7, 2019 05:01PM Ardelyx (ARDX) Announces Publication of Positive Phase 3 Results of Tenapanor for Treatment of Hyperphosphatemia in JASN
Mar 7, 2019 05:00PM Ardelyx Announces Peer-Reviewed Publication of Positive Phase 3 Results of Tenapanor for the Treatment of Hyperphosphatemia in the Journal of the American Society of Nephrology
Mar 6, 2019 04:05PM Ardelyx Reports Fourth Quarter 2018 Financial Results and Recent Highlights
Feb 21, 2019 08:00AM Ardelyx to Participate in Leerink Partners 8th Annual Global Healthcare Conference
Feb 7, 2019 06:36AM Ardelyx (ARDX) Collaboration Partner, Kyowa Hakko Kirin Commences Phase 2 Clinical Study of Tenapanor for Hyperphosphatemia Patients on Dialysis in Japan
Feb 7, 2019 06:30AM Ardelyx Collaboration Partner, Kyowa Hakko Kirin, Announces Initiation of a Phase 2 Clinical Study of Tenapanor for Hyperphosphatemia Patients on Dialysis in Japan
Nov 13, 2018 08:36AM Ardelyx (ARDX) Reports FDA Acceptance of NDA Filling for Tenapanor for Treatment of Patients with IBS-C
Nov 13, 2018 08:30AM Ardelyx Announces FDA Acceptance of the Filing of its New Drug Application for Tenapanor for the Treatment of Patients with IBS-C
Nov 7, 2018 04:05PM Ardelyx Reports Third Quarter 2018 Financial Results and Recent Highlights
Oct 26, 2018 01:40PM Ardelyx (ARDX) Reports New Preclinical Data Demonstrating Synergy between Tenapanor & Sevelamer When Dosed in Combination for Elevated Serum Phosphorus
Oct 26, 2018 01:01PM Ardelyx Presents New Preclinical Data Demonstrating Synergy between Tenapanor and Sevelamer When Dosed in Combination for Elevated Serum Phosphorus
Oct 8, 2018 08:01AM Ardelyx Showcases New Data from T3MPO-3 Long-Term Safety Trial of Tenapanor for IBS-C in Presidential Poster at ACG 2018 Annual Meeting
Oct 4, 2018 06:30AM Ardelyx to Host Its First Annual Investor Day Focused on Treatment Landscape of Renal Disorders
Sep 13, 2018 06:33AM Ardelyx (ARDX) Submits NDA for U.S. Marketing Authorization of Tenapanor for IBS-C to FDA
Sep 13, 2018 06:30AM Ardelyx Submits New Drug Application for U.S. Marketing Authorization of Tenapanor for IBS-C to U.S. Food and Drug Administration
Aug 29, 2018 02:16PM Ardelyx Announces Science Translational Medicine Publication Detailing Tenapanor's Unique Mechanism of Action Inhibiting Paracellular Phosphate Absorption
Aug 7, 2018 04:01PM Ardelyx Reports Second Quarter 2018 Financial Results and Recent Highlights
Aug 1, 2018 06:30AM Ardelyx Announces Date of Second Quarter 2018 Financial Results and Conference Call
May 29, 2018 06:30AM Ardelyx to Present at the Jefferies 2018 Global Healthcare Conference
May 21, 2018 04:02PM Ardelyx Raises $50 Million in Loan Agreement with Solar Capital and Bridge Bank
May 8, 2018 04:05PM Ardelyx Reports First Quarter 2018 Financial Results and Recent Business Highlights
Mar 19, 2018 06:30AM Ardelyx and Knight Collaborate to Bring Tenapanor to Patients in Canada
Mar 14, 2018 04:05PM Ardelyx Reports 2017 Financial Results and Appoints Industry Veteran, Jan Lundberg, Ph.D., to Board of Directors
Feb 12, 2018 06:34AM Ardelyx (ARDX) Reports Departure its Chief Scientific Officer
Feb 12, 2018 06:30AM Ardelyx Announces Departure of Chief Scientific Officer
Feb 8, 2018 06:30AM Ardelyx to Participate in Leerink Partners 7th Annual Global Healthcare Conference
Jan 3, 2018 06:37AM Ardelyx (ARDX) Reports Positive Results of T3MPO-3 Safety Extension Study of Tenapanor for IBS-C; Plans NDA Submission in 2H18
Jan 3, 2018 06:35AM Ardelyx Announces Presentation at J.P. Morgan 36th Annual Healthcare Conference
Jan 3, 2018 06:30AM Ardelyx Successfully Completes T3MPO-3 Safety Extension Study of Tenapanor for IBS-C
Dec 11, 2017 06:02AM Ardelyx (ARDX) Enters License Agreement with Shanghai Fosun for Tenapanor in China
Dec 11, 2017 06:00AM Ardelyx Announces License Agreement with Shanghai Fosun Pharmaceutical Industrial Development Company Limited for Tenapanor in China
Nov 28, 2017 05:50AM Ardelyx (ARDX) Reports Licensing Agreement with Kyowa Hakko Kirin for Tenapanor for Cardiorenal Diseases in Japan
Nov 28, 2017 02:00AM Ardelyx and Kyowa Hakko Kirin Announce License Agreement for Tenapanor for Cardiorenal Diseases in Japan
Nov 21, 2017 06:36AM Ardelyx (ARDX) Updates Development Path for Cardiorenal Pipeline
Nov 21, 2017 06:30AM Ardelyx Announces Updated Development Path for its Cardiorenal Pipeline
Nov 7, 2017 06:30AM Ardelyx Reports Third Quarter 2017 Operating Results and Clinical Progress
Oct 16, 2017 08:12AM Ardelyx (ARDX) Reports Data from Pre-Clinical Studies that Tenapanor Reduces Pain Caused by IBS-C Through Inhibition of TRPV-1 Signaling
Oct 16, 2017 08:01AM Ardelyx Announces Tenapanor Reduces Pain Caused by IBS-C Through Inhibition of TRPV-1 Signaling
Oct 11, 2017 04:03PM Ardelyx (ARDX) Says Phase 3 Study of Tenapanor for IBS-C Hit Primary and All Secondary Endpoints
Oct 11, 2017 04:02PM Ardelyx's Pivotal Phase 3 Study of Tenapanor for IBS-C Hits Primary and All Secondary Endpoints to Support NDA Submission in 2018
Aug 9, 2017 06:30AM Ardelyx Focuses Resources on Late-Stage Programs and Reports Second Quarter 2017 Operational Results
Aug 2, 2017 06:30AM Ardelyx Announces Date of Second Quarter Financial Results and Presentation at Wedbush PacGrow Healthcare Conference
View More Recent Stories View Older Stories